Drugs & Therapy Perspectives | 1999(14) articles
- Sermorelin : no sizable gains over somatropin
- Drug therapy limited in patients with Huntington's disease
- What can be done to stop the global threat of tuberculosis?
- Moxonidine a better tolerated centrally acting antihypertensive?
- Moxonidine trial in CHF halted because of safety concerns
- Prevention and disease management are worth the investment